Skip to main
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health is facing initial market challenges in terms of operating expenses and decline in US segment earnings, yet with a potential partnership with Novo Nordisk, it may diversify its targeted market for weight loss prescription drugs as an opportunity for future growth. However, with rising regulatory scrutiny and competition, Hims & Hers must strategically position itself and leverage its brand and offerings to remain a competitive player.

Bears say

Hims & Hers Health is facing multiple challenges that could negatively impact its long-term profitability and growth potential. These include potential regulatory challenges in the highly scrutinized GLP-1 market, potential erosion of customer lifetime value due to rising marketing costs, and the need to constantly optimize its business model to maintain unit economics. However, the company's renewed partnership with Novo Nordisk and strong early demand for its weight loss products provide a glimmer of hope for future growth. It remains to be seen if the company's investments in new specialties, international expansion, personalization, and strategic relationships will pay off and achieve its ambitious 2030 financial targets.

HIMS has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Buy based on their latest research and market trends.

According to 13 analysts, HIMS has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.